Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: ThermoGenesis

This article was originally published in The Gray Sheet

Executive Summary

ThermoGenesis: Private placement of about 1.6 mil. shares of common stock at $2.50 per share to a syndicate led by Biotechnology Development Fund and Chartwell Investment Partners nets approximately $3.8 mil. The Rancho Cordova, California company also issues three-year warrants representing the right to acquire an additional 163,900 shares of common stock at an exercise price of $3 per share. Proceeds will be used for "immediate short term capital needs" including preparation for marketing of the firm's CryoSeal system for harvesting adhesive and clotting proteins from blood plasma for wound-healing and therapeutic applications (510(k) pending), and the BioArchive placental/cord blood stem and progenitor cell transplant archiving system (first quarter 1998 510(k) submission). Gruntal & Co. and Oscar Gruss & Son were placement agents for the offering...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel